Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NTLA Intellia Therapeutics Inc

休市中 08-23 16:00:00 EDT

23.63

+0.63

+2.74%

盘后23.55

-0.08-0.34%

19:49 EDT

最高24.16	最低22.85	成交量106.08万
今开23.06	昨收23.00	日振幅5.69%
总市值24.00亿	流通市值22.51亿	总股本1.02亿
成交额2,517万	换手率1.11%	流通股本9,524万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NTLA","market":"US","secType":"STK","nameCN":"Intellia Therapeutics Inc","latestPrice":23.63,"timestamp":1724443200000,"preClose":23,"halted":0,"volume":1060794,"hourTrading":{"tag":"盘后","latestPrice":23.55,"preClose":23.63,"latestTime":"19:49 EDT","volume":42543,"amount":1005656.61,"timestamp":1724456989230},"delay":0,"floatShares":95240800,"shares":101579188,"eps":-5.476843,"marketStatus":"休市中","marketStatusCode":7,"change":0.63,"latestTime":"08-23 16:00:00 EDT","open":23.06,"high":24.16,"low":22.8511,"amount":25174415.267568,"amplitude":0.056909,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.476843,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1724659200000},"adr":0,"listingDate":1462507200000,"adjPreClose":23,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":22.8,"preClose":23,"latestTime":"09:27 EDT","volume":756,"amount":17424.53748,"timestamp":1724419620006},"postHourTrading":{"tag":"盘后","latestPrice":23.55,"preClose":23.63,"latestTime":"19:49 EDT","volume":42543,"amount":1005656.61,"timestamp":1724456989230},"volumeRatio":1.0358936038662685,"impliedVol":0.6376,"impliedVolPercentile":0.1706},"requestUrl":"/m/hq/s/NTLA/tweets","defaultTab":"tweets","newsList":[{"id":"2461016548","title":"Intellia Therapeutics, Inc.盘中异动 股价大涨5.04%报24.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461016548","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461016548?lang=zh_cn&edition=full","pubTime":"2024-08-24 01:05","pubTimestamp":1724432726,"startTime":"0","endTime":"0","summary":"北京时间2024年08月24日01时05分，Intellia Therapeutics, Inc.股票出现异动，股价急速拉升5.04%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.38%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240824010526ab5f70b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240824010526ab5f70b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","LU1861558580.USD","LU1861559042.SGD","BK4585","BK4556","BK4588","BK4139","BK4535","NTLA"],"gpt_icon":0},{"id":"2460312736","title":"Intellia Therapeutics, Inc.2024财年第二财季实现净利润-1.47亿美元，同比减少18.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460312736","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460312736?lang=zh_cn&edition=full","pubTime":"2024-08-18 00:00","pubTimestamp":1723910458,"startTime":"0","endTime":"0","summary":"8月18日，Intellia Therapeutics, Inc.公布财报，公告显示公司2024财年第二财季净利润为-1.47亿美元，同比减少18.55%；其中营业收入为6.96百万美元，同比减少48.79%，每股基本收益为-1.52美元。从资产负债表来看，Intellia Therapeutics, Inc.总负债2.20亿美元，其中短期债务18.96百万美元，资产负债比为5.42，流动比率为7.21。机构评级：截至2024年8月18日，当前有24家机构对Intellia Therapeutics, Inc.目标价做出预测，其中目标均价为69.17美元，其中最低目标价为24.00美元，最高目标价为144.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180001329f3402f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180001329f3402f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","NTLA"],"gpt_icon":0},{"id":"2459475041","title":"Intellia Therapeutics, Inc.盘中异动 快速上涨5.02%报22.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459475041","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459475041?lang=zh_cn&edition=full","pubTime":"2024-08-15 22:40","pubTimestamp":1723732835,"startTime":"0","endTime":"0","summary":"北京时间2024年08月15日22时40分，Intellia Therapeutics, Inc.股票出现波动，股价大幅拉升5.02%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.93%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081522403597198d59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081522403597198d59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NTLA","LENZ","BK4588","LU1861559042.SGD","LU1861558580.USD","BK4535","BK4556","BK4139","BK4585"],"gpt_icon":0},{"id":"2458749620","title":"美国研究综述-Airbnb、通用美元、沃尔玛","url":"https://stock-news.laohu8.com/highlight/detail?id=2458749620","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458749620?lang=zh_cn&edition=full","pubTime":"2024-08-12 15:40","pubTimestamp":1723448430,"startTime":"0","endTime":"0","summary":"    路透8月12日 - 华尔街证券分析师周一调整了对多家美国上市公司的评级和目标价，其中包括 Airbnb、Dollar General 和沃尔玛。要闻             * Airbnb Inc   ：杰富瑞将目标价从 150 美元下调至 125 美元              * Dollar General Corp   ：杰富瑞将目标价从160美元下调至145美元             * Hilton Grand Vacations Inc   ：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。* Pacira Biosciences Inc   ：摩根大通将目标价从45美元下调至10美元              * Pacira Biosciences Inc   ：Piper Sandler将目标价从42美元下调至11美元             * Pacira Biosciences Inc   ：Piper Sandler将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HGV","DG","PCRX","STEP","ZD","GHLD","NNI","LU1066051225.USD","LU2361044949.HKD","RDNT","HBI","DLTR","LEGH","BTAI","PX","IE0034390439.USD","LU2361044865.SGD","NTLA","GSHD","CBUS","BK4175","HLMN","ARDT","ROK","CC","EWTX","FMC","BJ","ABNB","FTDR","SWIM","GCMG","OKE","CARG","EXPE","SKY","BWIN","LU0211327993.USD","HSIC","CCOI","LU1069347547.HKD","BK4173","LU2361045086.USD","RDFN","BURL","OPAD","WMT","ITOS","BK4535"],"gpt_icon":1},{"id":"1134963682","title":"异动解读 | Intellia Therapeutics盘前大涨6.05% 基因编辑技术前景看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1134963682","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134963682?lang=zh_cn&edition=full","pubTime":"2024-08-09 16:08","pubTimestamp":1723190931,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc今日盘前大涨6.05%,报收于22.38美元/股。公司作为一家基因编辑公司,其基于CRISPR/Cas9技术的疗法前景受到市场青睐。Intellia Therapeutics专注于利用CRISPR/Cas9技术治疗基因定义的疾病。分析人士认为,随着基因编辑技术的不断进步,Intellia Therapeutics的产品线将获得更大发展空间。公司与诸如Regeneron和Novartis等大型制药公司建立了合作关系,有望推动其产品线快速发展。投资者对公司的长期增长前景持乐观态度,从而推动了股价的上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA"],"gpt_icon":0},{"id":"2458327519","title":"Intellia Therapeutics, Inc.盘中异动 临近收盘股价大涨5.02%报22.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458327519","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458327519?lang=zh_cn&edition=full","pubTime":"2024-08-09 04:00","pubTimestamp":1723147241,"startTime":"0","endTime":"0","summary":"北京时间2024年08月09日04时00分，Intellia Therapeutics, Inc.股票出现异动，股价急速拉升5.02%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为3.81%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809040041aefdf599&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809040041aefdf599&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","NTLA","BK4556","LENZ","BK4585","LU1861559042.SGD","BK4139","LU1861558580.USD","BK4535"],"gpt_icon":0},{"id":"2457791400","title":"Intellia Therapeutics Inc    预计每股亏损 1.23 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2457791400","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457791400?lang=zh_cn&edition=full","pubTime":"2024-08-07 01:24","pubTimestamp":1722965050,"startTime":"0","endTime":"0","summary":"   * Intellia Therapeutics Inc     将于8月8日公布截至2024年6月30日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，20位分析师的平均预期显示，这家总部位于马萨诸塞州剑桥市的公司的营收预计将从去年同期的1359万美元增长41.0%，达到1916.2万美元。* LSEG 的分析师平均预计 Intellia Therapeutics Inc 每股亏损 1.23 美元。* 华尔街对 Intellia Therapeutics Inc 的 12 个月目标价中位数为 70.00 美元，高于其上次收盘价 22.33 美元。8月6日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA","LENZ"],"gpt_icon":0},{"id":"2457776990","title":"Intellia Therapeutics, Inc.盘中异动 股价大跌6.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457776990","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457776990?lang=zh_cn&edition=full","pubTime":"2024-08-05 21:40","pubTimestamp":1722865222,"startTime":"0","endTime":"0","summary":"北京时间2024年08月05日21时40分，Intellia Therapeutics, Inc.股票出现异动，股价快速跳水6.81%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为2.18%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408052140229f107477&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408052140229f107477&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","NTLA","LU1861559042.SGD","LENZ","LU1861558580.USD","BK4535","BK4556","BK4139"],"gpt_icon":0},{"id":"2456468482","title":"Intellia Therapeutics, Inc.盘中异动 下午盘股价大跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2456468482","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456468482?lang=zh_cn&edition=full","pubTime":"2024-08-02 02:41","pubTimestamp":1722537709,"startTime":"0","endTime":"0","summary":"北京时间2024年08月02日02时41分，Intellia Therapeutics, Inc.股票出现波动，股价大幅跳水5.11%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.92%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802024149aefcbbde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802024149aefcbbde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","LU1861558580.USD","LU1861559042.SGD","BK4585","BK4556","BK4588","BK4139","BK4535","NTLA"],"gpt_icon":0},{"id":"2455298021","title":"Intellia Therapeutics Inc - Ntla-3001研究将招募最多30名患者。","url":"https://stock-news.laohu8.com/highlight/detail?id=2455298021","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455298021?lang=zh_cn&edition=full","pubTime":"2024-07-30 19:31","pubTimestamp":1722339115,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","NTLA","BK4556","BK4139","LENZ","BK4585","LU1861558580.USD","BK4535","LU1861559042.SGD"],"gpt_icon":0},{"id":"2454790802","title":"Intellia Therapeutics, Inc.盘中异动 急速上涨5.00%报26.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454790802","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454790802?lang=zh_cn&edition=full","pubTime":"2024-07-26 01:02","pubTimestamp":1721926942,"startTime":"0","endTime":"0","summary":"北京时间2024年07月26日01时02分，Intellia Therapeutics, Inc.股票出现波动，股价大幅拉升5.00%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072601022396820602&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072601022396820602&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NTLA","LU1861559042.SGD","BK4556","BK4535","BK4588","BK4139","BK4585","LENZ","LU1861558580.USD"],"gpt_icon":0},{"id":"2453061259","title":"Intellia Therapeutics, Inc.盘中异动 快速拉升5.01%报26.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453061259","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453061259?lang=zh_cn&edition=full","pubTime":"2024-07-24 03:07","pubTimestamp":1721761664,"startTime":"0","endTime":"0","summary":"北京时间2024年07月24日03时07分，Intellia Therapeutics, Inc.股票出现异动，股价快速上涨5.01%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240724030744aefb09a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240724030744aefb09a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","LU1861559042.SGD","LU1861558580.USD","BK4585","BK4556","NTLA","BK4139","BK4588","BK4535"],"gpt_icon":0},{"id":"2446558171","title":"加拿大投资银行集团：维持Intellia Therapeutics(NTLA.US)评级，由买入调整至买入评级, 目标价由73.","url":"https://stock-news.laohu8.com/highlight/detail?id=2446558171","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446558171?lang=zh_cn&edition=full","pubTime":"2024-06-27 21:37","pubTimestamp":1719495459,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4556","LU1861559042.SGD","BK4535","LENZ","LU1861558580.USD","NTLA","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"2446236136","title":"Intellia Therapeutics Inc - 任命Edward Dulac为CFO生效日期为2024年7月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=2446236136","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446236136?lang=zh_cn&edition=full","pubTime":"2024-06-26 19:30","pubTimestamp":1719401408,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1861559042.SGD","BK4588","BK4556","LU1861558580.USD","BK4139","NTLA","BK4535","BK4585","LENZ"],"gpt_icon":0},{"id":"2446007110","title":"BUZZ-Alnylam 因心脏病药物在关键研究中获得成功而跃升","url":"https://stock-news.laohu8.com/highlight/detail?id=2446007110","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446007110?lang=zh_cn&edition=full","pubTime":"2024-06-25 01:42","pubTimestamp":1719250931,"startTime":"0","endTime":"0","summary":" (更新)    6月24日 - ** Alnylam Pharmaceuticals  股价大涨40%至231.64美元，创下自2023年2月以来的最高水平 。** 如果涨势保持，市值将增加80多亿美元** 该公司称其心脏病药物vutrisiran在一项受到密切关注的后期研究中达到了  主要目标和所有次要目标** 该药物vutrisiran有助于将一种被称为ATTR-CM的罕见心脏病患者的死亡人数和心脏相关住院治疗人数减少33%。** ALNY 公司的药物通过关闭转甲状腺素蛋白的不规则生产而发挥作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NTLA","BK4556","LU1861559042.SGD","BK4139","BUZZ","ALNY","BK4505","IONS","BBIO","BK4585","LU1861558580.USD","BK4535","BK4548"],"gpt_icon":0},{"id":"2440484252","title":"当地时间2024年6月2日，据生物医药行业媒体Endpoints News 报道，在西班牙Valencia举行的欧洲过敏与临床免疫学学会上，基因编辑公司Intellia Therapeutics（NTLA.","url":"https://stock-news.laohu8.com/highlight/detail?id=2440484252","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440484252?lang=zh_cn&edition=full","pubTime":"2024-06-03 11:00","pubTimestamp":1717383636,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["LU1861559042.SGD","161726","BK4588","BK4535","399441","NTLA","LENZ","BK4585","BK4139","LU1861558580.USD","BK4556","CRSP"],"gpt_icon":0},{"id":"2440128599","title":"Intellia Therapeutics公布了正在进行的Ntla-2002的1期研究的积极长期数据Ntla-2002是一种用于遗传性血管性水肿（Hae）的在研CRISPR基因编辑疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2440128599","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440128599?lang=zh_cn&edition=full","pubTime":"2024-06-02 20:05","pubTimestamp":1717329953,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics公布了正在进行的Ntla-2002的1期研究的积极长期数据Ntla-2002是一种用于遗传性血管性水肿（Hae）的在研CRISPR基因编辑疗法","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406022005539f11ff88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406022005539f11ff88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRSP","BK4588","BK4556","LU1861558580.USD","LU1861559042.SGD","BK4139","NTLA","BK4535","BK4585","LENZ"],"gpt_icon":0},{"id":"2436945444","title":"Intellia Therapeutics, Inc.2024财年第一财季实现净利润-1.07亿美元，同比减少3.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436945444","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2436945444?lang=zh_cn&edition=full","pubTime":"2024-05-18 00:26","pubTimestamp":1715963160,"startTime":"0","endTime":"0","summary":"3月31日，Intellia Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-1.07亿美元，同比减少3.88%；其中营业收入为28.94百万美元，同比增加129.50%，每股基本收益为-1.13美元。从资产负债表来看，Intellia Therapeutics, Inc.总负债2.23亿美元，其中短期债务18.76百万美元，资产负债比为5.66，流动比率为0.10。机构评级：截至2024年3月31日，当前有23家机构对Intellia Therapeutics, Inc.目标价做出预测，其中目标均价为68.17美元，其中最低目标价为24.00美元，最高目标价为144.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180026058b131d6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180026058b131d6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NTLA","LENZ"],"gpt_icon":0},{"id":"2434855383","title":"美国研究综述-Cerence、Epam Systems、Progyny","url":"https://stock-news.laohu8.com/highlight/detail?id=2434855383","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2434855383?lang=zh_cn&edition=full","pubTime":"2024-05-10 20:39","pubTimestamp":1715344798,"startTime":"0","endTime":"0","summary":"    路透5月10日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Cerence、Epam Systems 和 Progyny。要闻  * Cerence Inc   ：富国银行将其评级从 \"增持 \"下调至 \"等权重\"。* Epam Systems Inc   ：丰业银行将其评级从 \"跑赢大市 \"下调至 \"行业表现\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HBI","FLNC","CMI","LYFT","BK4548","LU1815336091.USD","BK4113","OXY","CPAY","GO","LU2463526074.USD","BK4533","AVAH","BIGC","CRL","FOLD","GFF","HLIO","ARWR","MRC","LU0053671581.USD","IFF","APLT","LU0320765992.SGD","ARHS","YOU","GAIN","EYE","LU0823414478.USD","ANIK","MRCY","MGNX","MKSI","CRNX","FDMT","GRWG","BK4227","OBDC","PGNY","NTLA","EPAM","MTRN","BK4109","ACAD","FWRD","IE00B66KJ199.SGD","BRT","CE","NTRA","BK4539"],"gpt_icon":0},{"id":"2433200845","title":"Intellia Therapeutics Inc    预计每股亏损 1.38 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2433200845","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2433200845?lang=zh_cn&edition=full","pubTime":"2024-05-07 21:33","pubTimestamp":1715088805,"startTime":"0","endTime":"0","summary":"   * Intellia Therapeutics Inc     5月9日发布的截至2024年3月31日的财报显示，该公司的季度营收预计将出现下降。* 根据LSEG的数据，16位分析师的平均预期显示，这家总部位于马萨诸塞州剑桥市的公司的营收将从去年同期的1261万美元降至1150.4万美元，降幅为8.7%。* LSEG 的分析师平均预计 Intellia Therapeutics Inc 每股亏损 1.38 美元。* 华尔街对 Intellia Therapeutics Inc 的 12 个月目标价中位数为 70.00 美元，高于其最新收盘价 23.72 美元。5月7日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NTLA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.intelliatx.com","stockEarnings":[{"period":"1week","weight":0.0442},{"period":"1month","weight":-0.077},{"period":"3month","weight":-0.0487},{"period":"6month","weight":-0.0946},{"period":"1year","weight":-0.3702},{"period":"ytd","weight":-0.225}],"compareEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":0.0386},{"period":"3month","weight":0.0617},{"period":"6month","weight":0.1069},{"period":"1year","weight":0.2867},{"period":"ytd","weight":0.1827}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Intellia Therapeutics, Inc.于2014年5月在特拉华州注册成立。该公司是一家领先的基因编辑公司，专注于利用最近开发的被称为CRISPR/ Cas9的系统生物工具进行的独特的、潜在治愈疗法的发展。公司认为CRISPR/ Cas9技术具有通过单一疗程永久编辑疾病相关的基因在人体内进行改造药物的潜力。该公司打算利用其领先的科学专业知识、临床开发经验和知识产权地位解锁CRISPR/ Cas9基因编辑广泛的治疗应用，发展有潜能的新一代治疗产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.014871},{"month":2,"riseRate":0.75,"avgChangeRate":0.078068},{"month":3,"riseRate":0.25,"avgChangeRate":-0.040105},{"month":4,"riseRate":0.375,"avgChangeRate":-0.074095},{"month":5,"riseRate":0.25,"avgChangeRate":0.030737},{"month":6,"riseRate":0.888889,"avgChangeRate":0.214578},{"month":7,"riseRate":0.555556,"avgChangeRate":0.022335},{"month":8,"riseRate":0.555556,"avgChangeRate":0.031166},{"month":9,"riseRate":0.125,"avgChangeRate":-0.068112},{"month":10,"riseRate":0.25,"avgChangeRate":-0.059832},{"month":11,"riseRate":0.625,"avgChangeRate":0.121561},{"month":12,"riseRate":0.375,"avgChangeRate":-0.073139}],"exchange":"NASDAQ","name":"Intellia Therapeutics Inc","nameEN":"Intellia Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Intellia Therapeutics Inc,NTLA,Intellia Therapeutics Inc股票,Intellia Therapeutics Inc股票老虎,Intellia Therapeutics Inc股票老虎国际,Intellia Therapeutics Inc行情,Intellia Therapeutics Inc股票行情,Intellia Therapeutics Inc股价,Intellia Therapeutics Inc股市,Intellia Therapeutics Inc股票价格,Intellia Therapeutics Inc股票交易,Intellia Therapeutics Inc股票购买,Intellia Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}